• SENSEX
    NIFTY 50
Healthcare

Ipca Labs, Cadila Health 'could be at risk' as USFDA cautions on use of hydroxychloroquine

Updated : April 27, 2020 03:08 PM IST

The USFDA stated that HCQS use should be limited to clinical trials or treating certain hospitalized patients.
Ipca Labs and Cadila Healthcare fell up to 5 percent on Monday post this development.
Ipca Labs and Cadila Healthcare have risen over 40 percent and 30 percent, respectively in 2020.
Ipca Labs, Cadila Health 'could be at risk' as USFDA cautions on use of hydroxychloroquine

You May Also Like

Live TV
Advertisement